Journal: JPRAS Open

Article Title: Long-term results of lymphedema treatment with Combined lymph node transfer and collagen scaffolds: An Observational Study

doi: 10.1016/j.jpra.2024.11.019

Figure Lengend Snippet: Illustrations showing the area of lymph node flap transfer at the groin (LNT), and BioBridge® NCS insertion at the subdermal level along the blue lines (inner area of the limb).

Article Snippet: BioBridge® NCS consist of parallel aligned porcine type I atelocollagen nanofibers., Their similar structure to the natural arrangement of human collagen fibers in connective tissue, promotes endothelial cell migration, attachment, and outgrowth, as reported by Nakayama et al., who tested arteriogenesis in the context of peripheral arterial disease.

Techniques:

Journal: The Journal of nutrition

Article Title: Antiangiogenic effects of indole-3-carbinol and 3,3'-diindolylmethane are associated with their differential regulation of ERK1/2 and Akt in tube-forming HUVEC.

doi: 10.3945/jn.109.112359

Figure Lengend Snippet: FIGURE 2 Inhibition of tube formation and induction of apoptosis in tube-forming HUVEC by ERK1/2 inactivation (U0126) and Akt inacti- vation (LY294002). Endothelial cells were induced to form blood vessel-like tubes and were treated with vehicle, U0126 (10 mmol/L), LY294002 (LY2) (5 mmol/L), or U0126 (10 mmol/L) + LY294002 (5 mmol/L) for 24 h. (Left panel) Reduction of the tube network by U0126 and LY294002. Bar indicates 100 mm. (Right panel) Induction of chromatin condensation and nuclear fragmentation by U0126 and LY294002. Bar indicates 50 mm.

Article Snippet: DIM was purchased from LKT Laboratories, MCDB-104 medium from Nihon Pharmaceutical, fetal bovine serum (FBS) from Moregate, Atelocollagen Bovine Dermis (type I collagen) from Koken, epidermal growth factor from BD Biosciences, human bFGF (recombinant) from Austral Biologicals, U0126 from Calbiochem, and LY294002 from Cell Signaling Technology.

Techniques: Inhibition

Journal: Cancer Science

Article Title: Nobiletin, a citrus polymethoxyflavonoid, suppresses multiple angiogenesis‐related endothelial cell functions and angiogenesis in vivo

doi: 10.1111/j.1349-7006.2010.01668.x

Figure Lengend Snippet: Nobiletin inhibited both vascular endothelial growth factor (VEGF)‐ and basic fibroblast growth factor (bFGF)‐induced angiogenic differentiation. (A) Human umbilical vein endothelial cells were cultured between the two layers of collagen gel with vehicle or nobiletin in the presence or absence of VEGF and bFGF for 24 h. Representative images are shown. (B) The formed tube area per field was determined. Values are expressed as means ± SE (n = 3). *P < 0.05, **P < 0.01, as compared with the control.

Article Snippet: Fetal bovine serum (FBS) was purchased from Moregate (Melbourne, Australia), plasminogen for chromogenic substrate assay form Roche Applied Science (Hague Lord, IN, USA), matrigel from Becton, Dickinson and Company (Franklin Lakes, NJ, USA), Atelocollagen bovine dermis (type I collagen) from Koken (Tokyo, Japan), human recombinant vascular endothelial growth factor (VEGF) from Humanzyme (Chicago, IL, USA) and human recombinant basic fibroblast growth factor (bFGF) from WAKO (Osaka, Japan).

Techniques: Cell Culture

Journal: Cancer Science

Article Title: Nobiletin, a citrus polymethoxyflavonoid, suppresses multiple angiogenesis‐related endothelial cell functions and angiogenesis in vivo

doi: 10.1111/j.1349-7006.2010.01668.x

Figure Lengend Snippet: Nobiletin attenuated the phosphorylation of both vascular endothelial growth factor (VEGF)‐ and basic fibroblast growth factor (bFGF)‐induced signaling and transcriptional molecules, and evoked activation of the caspase pathway in tube‐forming human umbilical vein endothelial cells (HUVEC). The tube‐forming HUVEC were treated with vehicle or nobiletin in the presence or absence of VEGF and bFGF for 2 h (A‐D) or 12 h (E). Representative images are shown. Values are expressed as means ± SE (n = 3). NA, no angiogenic factor; Con, control; N, nobiletin. *P < 0.05, **P < 0.01, as compared with the control.

Article Snippet: Fetal bovine serum (FBS) was purchased from Moregate (Melbourne, Australia), plasminogen for chromogenic substrate assay form Roche Applied Science (Hague Lord, IN, USA), matrigel from Becton, Dickinson and Company (Franklin Lakes, NJ, USA), Atelocollagen bovine dermis (type I collagen) from Koken (Tokyo, Japan), human recombinant vascular endothelial growth factor (VEGF) from Humanzyme (Chicago, IL, USA) and human recombinant basic fibroblast growth factor (bFGF) from WAKO (Osaka, Japan).

Techniques: Activation Assay